An Ongoing Phase 1 Study of ABT-263; Pharmacokineties, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

被引：0
|
作者：
Roberts, Andrew W. [1 ]
Brown, Jennifer [2 ]
Seymour, John F. [3 ]
Wierda, William G. [4 ]
Kipps, Thomas J. [5 ]
Xiong, Hao [6 ]
Chiu, Yi-Lin [6 ]
Busman, Todd [6 ]
Knight, Raymond A. [6 ]
Enschede, Sari [6 ]
Krivoshik, Andrew [6 ]
Humerickhouse, Rod [6 ]
机构：
[1] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haem, Parkville, Vic 3050, Australia
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Australia
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] CLL Res Consortium, Moores UCSD Canc Ctr, La Jolla, CA USA
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1089 / 1090
页数：2
相关论文
共 50 条
  • [31] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barr, Paul M.
    Ma, Shuo
    Zent, Clive S.
    Baran, Andrea M.
    Bui, Andrew
    Meacham, Philip J.
    Morrison, Ashley
    Holkovic, Kelsey
    Liesveld, Jane L.
    Mulford, Deborah A.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Hill, Brian T.
    BLOOD, 2020, 136
  • [32] Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
    Bergmann, Manuela A.
    Goebeler, Maria E.
    Herold, Michael
    Emmerich, Bertold
    Wilhelm, Martin
    Ruelfs, Corinna
    Boening, Lothar
    Hallek, Michael J.
    HAEMATOLOGICA, 2005, 90 (10) : 1357 - 1364
  • [33] Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
    Woyach, Jennifer Ann
    Flynn, Joseph M.
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, Margaret
    Chase, Weihong
    Yang, Ying
    Lucas, David M.
    Sass, Ellen
    Waymer, Sharon
    Ling, Yonghua
    Jiang, Yao
    Phelps, Mitch A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Barr, Paul M.
    Hill, Brian T.
    Ma, Shuo
    Baran, Andrea M.
    Bui, Andrew
    Meacham, Philip J.
    Morrison, Ashley
    Liesveld, Jane L.
    Mulford, Deborah A.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Zent, Clive S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 9 - 10
  • [35] Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
    Wendtner, Clemens-Martin
    Hillmen, Peter
    Mahadevan, Daruka
    Buehler, Andreas
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David D.
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    Moutouh-de Parseval, Laure
    Hallek, Michael
    Heerema, Nyla A.
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 417 - 423
  • [36] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 20
  • [37] Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Garcia-Marco, Jose
    Tello, Patricia Baltasar
    Garcia, Esther Gonzalez
    Herranz, Eduardo Rios
    Payer, Angel Ramirez
    Castera, Maria Jose Terol
    Champ, Diana
    Perez, Angeles Medina
    Gironella, Mercedes
    Fernandez, Alicia Rodriguez
    Prat, Ana Muntanola
    Cabrera, Alexia Suarez
    Chacon, Manuel Jurado
    Zarzoso, Miguel Fernandez
    Rodriguez, Mercedes
    Clavel, Juana
    Sahun, Maria Victoria Dourdil
    Coll, Christelle M. Ferra
    Persona, Ernesto Perez
    Santos, Carmen Milagros Marrero
    Fores, Rafael
    Delgado, Julio
    BLOOD, 2017, 130
  • [38] Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed of refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
    Terui, Y.
    Ogura, M.
    Tobinai, K.
    Hatake, K.
    Suzuki, T.
    Muruyama, D.
    Miyazato, A.
    Katsura, K.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel in Combination With Ibrutinib for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 18 - 19
  • [40] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
12345